Preclinical Development
The Preclinical Development grant from the California Institute for Regenerative Medicine funds preclinical research to advance stem cell and genetic therapies to IND clearance and clinical trial readiness.
Funder: California Institute for Regenerative Medicine
Due Dates: October 8, 2026 (PDEV full application deadline)
Funding Amounts: Up to $13,000,000 per award | Maximum duration: 5 years | Typical awards fund 7–12 projects per cycle
Summary: Supports preclinical development of stem cell-based or genetic therapies to achieve FDA IND clearance and enable clinical trial startup.
Key Information: Applicant must be a California Organization; project must aim for IND clearance for a single therapy candidate.
Description
This program funds preclinical research to advance stem cell-based and genetic therapy candidates toward FDA Investigational New Drug (IND) clearance and clinical trial readiness. The initiative aims to accelerate transformative therapies for diseases affecting Californians, particularly those that address significant barriers to patient access. The program provides substantial funding and expert partnership to help projects achieve critical regulatory milestones and move efficiently toward first-in-human clinical trials.
